重型再生障碍性贫血治疗进展  

Treatment progress of severe aplastic anemia

作　　者：季艳萍 孙自敏 Ji Yanping;Sun Zimin(Department of Hematology,the First Affiliated Hospital of University of Science and Technology of China,Hefei 230001,China)

机构地区：[1]中国科学技术大学附属第一医院血液科,合肥230001

出　　处：《器官移植》2020年第2期293-297,310,共6页Organ Transplantation

基　　金：国家自然科学基金(81470350);中央高校基本科研业务费专项资金(WK9110000001)。

摘　　要：重型再生障碍性贫血(SAA)是一类少见的骨髓造血功能衰竭性疾病,与患者体内毒性T淋巴细胞为主的免疫功能紊乱、造血微环境的异常和造血干细胞的损伤相关。SAA起病急、进展快、病情重且致死率高,需快速并稳定地恢复患者造血功能。本文就免疫抑制剂疗法(IST)治疗SAA、同胞人类白细胞抗原(HLA)全相合异基因造血干细胞移植(allo-HSCT)治疗SAA、替代供者造血干细胞移植治疗SAA、非血缘脐血造血干细胞移植治疗SAA等方面的治疗进展进行综述。Severe aplastic anemia(SAA)is a rare type of bone marrow hematopoietic failure,which is associated with toxic T lymphocyte-based immune dysfunction,abnormal hematopoietic microenvironment and damage of hematopoietic stem cells in patients.SAA characterized by acute onset,rapid progression and high mortality rate,which requires rapid and stable recovery of the patients'hematopoietic function.In this article,the therapeutic progresses on immunosuppressive therapy(IST),sibling human leukocyte antigen(HLA)-matched allogenetic hematopoietic stem cell transplantation(allo-HSCT),replacement of donor hematopoietic stem cell transplantation and unrelated umbilical cord blood hematopoietic stem cell transplantation(UCBT)for SAA were reviewed.

关 键 词：重型再生障碍性贫血 人类白细胞抗原 免疫抑制剂疗法 单倍型造血干细胞移植 总生存率 抗胸腺细胞球蛋白 异基因造血干细胞移植 脐血造血干细胞移植 移植物抗宿主病 

分 类 号：R617[医药卫生—外科学] R556.5[医药卫生—临床医学]